Psychedelics as catalysts of insight-oriented psychotherapy

Social Research

Volumn 68, Issue 3, 2001, Pages 676-695

  Grinspoon, Lester ^a   Doblin, Rick ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0035457924     PISSN: 0037783X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Abramson, H. A., ed. The Use of LSD in Psychotherapy and Alcoholism. New York: Bobbs-Merrill, 1967.
2. Aghajanian, G., and J. Lieberman. "Response." Neuropsychopharmacology 24:3 (2001): 335-336.
3. Albaugh, B. J., and P. O. Anderson. "Peyote in the Treatment of Alcoholism among American Indians." American Journal of Psychiatry 131 (1974): 1247-51.
4. Berman, R. M., et al. "Antidepressant Effects of Ketamine in Depressed Patients." Biological Psychiatry 47:4 (Feb. 15, 2000): 351-4.
5. Bonny, H., and L. Savary. Music and Your Mind: Listening with a New Consciousness. New York: Harper and Row, 1973.
6. Cheek, F. E., H. Osmond, M. Sarett, and R. S. Albahary. "Observations Regarding the Use of LSD-25 in the Treatment of Alcoholism." Journal of Psychopharmacology 1 (1966): 56-74.
7. Cohen, S. "Lysergic Acid Diethylamide. Side Effects and Complications." Journal of Nervous and Mental Disease 130 (1960): 30-40.
8. DeBold, R. C., and Russell C. Leaf, eds. LSD, Man, and Society. Middletown, Conn.: Wesleyan University Press, 1967.
9. Delgado, P. L., and F. A. Moreno. "Hallucinogens, serotonin and Obsessive-Compulsive Disorder." Journal of Psychoactive Drugs 30:4 (Oct.-Dec., 1998): 359-66.
10. Furst, P. T. Hallucinogens and Culture. San Francisco: Chandler and Sharp, 1976.
11. Gasser, P. "Psycholytic Therapy with MDMA and LSD in Switzerland: Follow-up Study on the Results of Swiss Research Conducted during 1988-1993." Bulletin of the Multidisciplinary Association for Psychedelic Studies 5:3 (Winter, 1994-1995): 3-7.
12. Gomes-Schwartz, B. "Effective Ingredients in Psychotherapy: Prediction of Outcome from Process Variables." Journal of Consulting and Clinical Psychology 46 (1978): 1023-35.
13. Grinspoon, L., and J. B. Bakalar. Psychedelic Drugs Reconsidered. New York: Basic Books, 1979.
14. Grof, S., et al. "LSD-assisted Psychotherapy in Patients with Terminal Cancer." International Pharmacopsychiatry 8 (1973): 129-41.
15. Hoffer, A. "A Program for the Treatment of Alcoholism: LSD, Malvaria, and Nicotinic Acid." The Use of LSD in Psychotherapy and Alcoholism. Ed. H. Abramson. New York: Bobbs-Merrill, 1967: 353-402.
16. Krupitsky, E. M., and A. Y. Grinenko. "Ketamine Psychedelic Therapy (KPT): A Review of the Results of Ten Years of Research." Journal of Psychoactive Drugs 29:2 (Apr-Jun, 1997): 165-83.
17. Kurland, A. A. "The Therapeutic Potential of LSD in Medicine." DeBold and Leaf (1967): 20-35.
18. Liester, M. B., et al. "Phenomenology and Sequelae of 3,4-methylenedioxymethamphetamine Use." Journal of Nervous and Mental Disease 180:6 (June 1, 1992a): 345-52; discussion, 353-4.
19. -. "Discussion." Journal of Nervous and Mental Disease 180:6 (June 1, 1992b): 353-4.
20. Malleson, N. "Acute Adverse Reactions to LSD in Clinical and Experimental Use in the United Kingdom." British Journal of Psychiatry 118 (1971): 229-230.
21. Mash, D. C., et al. "Ibogaine: Complex Pharmacokinetics, Concerns for Safety, and Preliminary Efficacy." Annals of the New York Academy of Sciences - Neurobiological Mechanisms of Drugs of Abuse. 94 (2000): 394-401.
22. McCann, U. D., et al. "Positron Emission Tomographic Evidence of Toxic Effect of MDMA ("Ecstasy") on Brain Serotonin Neurons in Human Beings." Lancet 352:9138 (Oct 31, 1998): 1433-7.
23. McCann, U., and G. Ricaurte. "Caveat Emptor: Editors Beware." Neuropsychopharmacology 24:3 (2001): 333-334.
24. Moras, K., and H. H. Strupp. "Pretherapy Interpersonal Relations, Patient's Alliance, and Outcome in Brief Therapy." Archives of General Psychiatry 39 (April 1982): 405-9.
25. Naranjo, C. The Healing Journey. New York: Ballantine Books, 1975 [1973].
26. Newland, C. A. Myself and I. New York: American Library, 1962.
27. Pahnke, W. N. "The Psychedelic Mystical Experience in the Human Encounter with Death." Harvard Theological Review 62 (1969): 1-21.
28. Riedlinger, J. E. "The Scheduling of MDMA: A Pharmacist's Perspective" Journal of Psychoactive Drugs 17 (1985): 167-71.
29. Savage, C., D. Jackson, and J. Terrill. "LSD, Transcendence, and the New Beginning." Journal of Nervous and Mental Disease 135 (1962): 425-39.
30. Seymour, R. B. "MDMA: Another View of Ecstasy." Pharm Chem Newsletter 14 (1985): 1-5.
31. Shagass, C., and R. M. Bittle. "Therapeutic Effects of LSD: A Follow-up Study." Journal of Nervous and Mental Disease 144 (1967): 471-78.
32. Smart, R. G., et al. "A Controlled Study of Lysergide in the Treatment of Alcoholism." Quarterly Journal of Studies in Alcoholism 27 (1984): 469-482.
33. Stolaroff, M. The Secret Chief. Charlotte, N.C.: Multidisciplinary Association for Psychedelic Studies, 1997.
34. Strassman, R. J. "Adverse Reactions to Psychedelic Drugs: A Review of the Literature." Journal of Nervous and Mental Disease 172 (1984): 577-95.
35. Vanggard, T. "Indications and Counterindications for LSD Treatment." Acta Psychiatrica Scandinavica 40 (1964): 427-37.
36. Vollenweider, F. X., A. Gamma, M. Liechti, and T. Huber. "Psychological and Cardiovascular Effects and Short-term Sequelae of MDMA ("Ecstasy") in MDMA-naive Healthy Volunteers." Neuropsychopharmacology 4 (Oct. 19, 1998): 241-51.
37. -. "Is a Single Dose of MDMA Harmless?" Neuropsychopharmacology 21:4 (Oct. 1999): 598-600.
38. Vollenweider, F., R. Jones, and M. Baggott. "Caveat Emptor: Editors Beware." Neuropsychopharmacology 24:4 (2001): 461-463.
39. Yensen, R., et al. "MDA-assisted Psychotherapy with Neurotic Outpatients: A Pilot Study." Journal of Nervous and Mental Disease 163 (1976): 233-45.